Other Headlines

Advocacy groups applaud passage of bill that would permanently repeal and replace SGR.
The medical community pays tribute to a dedicated crew.
The "germ theory" of schizophrenia got a mild boost this week as scientists discover that recently afflicted schizophrenics show higher levels of inflammatory proteins in the brain.
A novel microfluidic drug delivery system makes it possible to reach parts of the body poorly served by oral and injectable medications.
Thanks to a European grant for the HyperIMAGE project, a consortium of scientists across Europe have worked with Philips to develop a proof-of-concept, pre-clinical combined MR-PET scanner that could one day lead to improved radiation therapy and cardiology treatments.

Have News for Us?

Submit your news on the industry, people, or companies.

Forward to a Friend

More Industry Headlines

House Passes Medicare Physician Payment Reform Act Advocacy groups applaud passage of bill that would permanently repeal and replace SGR.

Scientists Find Unusual Immune System Activity in Brains of Schizophrenics The "germ theory" of schizophrenia got a mild boost this week as scientists discover that recently afflicted schizophrenics show higher levels of inflammatory proteins in the brain.

Aural Trumps Oral for Ear Treatment A novel microfluidic drug delivery system makes it possible to reach parts of the body poorly served by oral and injectable medications.

Clinical PET-MRI Moves Closer to Reality Thanks to a European grant for the HyperIMAGE project, a consortium of scientists across Europe have worked with Philips to develop a proof-of-concept, pre-clinical combined MR-PET scanner that could one day lead to improved radiation therapy and cardiology treatments.

Senate Health Care Reform Bill Unveiled Legislation may go to cloture vote this weekend. Read the details.

RSNA 2009 Preview This year's RSNA should provide a very interesting look at the effects of the economy on the major OEMs. As always, vendors are whipping up the hoopla, and inside this story are great previews of what's being debuted. But DOTmed reporters will also be there to get the real buzz. Look for video interviews in our Online News direct from the show.

Interview With Fred Robertson, President & CEO of TomoTherapy TomoTherapy president and CEO Fred Robertson talks with DOTmed about his perspective on ASTRO's 2009 annual meeting, changes in the radiation oncology industry and two important TomoTherapy product launches that occurred at the show. Watch the HD video.

Pen-Sized Microscope Aims for Precise Brain Surgeries A confocal microscope picking up brain-safe fluorescent dyes could result in more accurate and streamlined surgeries to remove tumors from the brain.

Health Care Reform Round-Up: CBO Pegs Senate Bill at $849 Billion The numbers are in on the Senate's version of reform. Also read about the wide-ranging impact that the legislation would have.

U.S. Preventive Services Task Force Has Stunning New Guidelines on Mammography Agency recommends no routine screening for women 40-49, no self-examination. Read the details.

"What's up doc?"
Naked mole rats
are immune to cancer

Researchers Check Suspicious Looking Mole (Rat)

by Jennifer Madison, DOTmed News Reporter
There is one species that's winning the rat race against cancer, and researchers are uncovering why the hairless animal is so superior. Scientists at the University of Rochester in New York are studying the naked mole rat, the only known animal immune to cancer; and they hope the buck-toothed creature will unlock long-standing mysteries surrounding the disease -- and help humans find a cure.

The naked mole rat is among several types of burrowing rodents, a diverse species widely used for scientific research. Their lifespan of up to 30 years is staggeringly long for the species. And three decades of life is certainly enough time for most animals to develop cancerous cells. However, unlike mice and humans -- two species often used in cancer research -- cancerous tumors have never been found in the mole rat.

The animal has a unique genetic defense against the disease according to head researcher Vera Gorbunova, associate professor of biology; her associate Andrei Seluanov, research professor of biology; and their colleagues at the university. The findings of their studies are shared in the October issue of The Proceedings of the National Academy of Sciences.

According to the study, the naked mole rat shares a gene with humans and many other animals called p27, which prevents the overcrowding among cells that can lead to cancer. However, researchers have now uncovered a second defense uniquely possessed by naked mole rats.

As part of the study, Gorbunova and her team attempted to mutate cells in the rodents in an effort to induce tumors. However, they found that the p16 gene found in the creatures provides a highly pronounced cancer-proof effect. Cells refused to replicate in the animals due to their evolved defense system, preventing overcrowding at a rate much earlier than in other animals. Gorbunova explains, "We realized that whatever was doing this was probably the same thing that prevented cancer from ever getting started in the mole rats."

Before stumbling upon the naked mole rat's cancer-proof system, Gorbunova and Seluanov investigated other rodent species around the world in an effort to better understand cancer and its effect. She recalls, "We were interested in comparative biology of aging and were studying short- and long-lived rodent species. (The) naked mole rat stood out by being an exceptionally long-lived and cancer-free rodent. We suspected that naked mole rats may use a novel anticancer mechanism that is not found in mice or humans."

Through their testing methods, any other species would have become cancerous. Gorbunova admits she was stunned by the findings, which she calls "a bit of a surprise."

However, she is hesitant to theorize how her research could affect cancer research in humans and other species. She explains, "It's very early to speculate about the implications." On expanding her research she adds, "We are working to identify the triggers of early contact inhibition with the hope of using those molecules to arrest the growth of cancer cells."

Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

Please Send us your Comments.

Printable Story
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2009 DOTmed.com, Inc.
ALL RIGHTS RESERVED